IPO

Chinese biotech's $53m IPO joins flurry of HK market activity

Even if Hong Kong's social landscape remains fractured, biotech firms continue to be lured to the HKEX, with Ascentage Pharma the latest to float.
October 23, 2019

Suzhou-based biotech firm Ascentage Pharma has raised HK$410m ($53 million) in a Hong Kong IPO according to a deal term sheet, as trendy biotech listings prevail amid social tensions.

¬ Haymarket Media Limited. All rights reserved.

Sign in to read on!

Registered users get 2 free articles in 30 days.

Subscribers have full unlimited access to FinanceAsia.

Not signed up? New users get 2 free articles per month, plus a 7-day unlimited free trial.

Questions?
See here for more information on licences and prices, or contact [email protected].

Share our publication on social media
Share our publication on social media